November 7, 2008
A Stakeholder Insight Report on the Osteoporosis Market Reveals That Generic Alendronate Further Establishes Oral Bisphosphonates As a Gold Standard
Research and Markets (http://www.researchandmarkets.com/research/4a693a/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Osteoporosis - Generic Alendronate Further Establishes Oral Bisphosphonates as Gold Standard" report to their offering.
Almost 100 million post-menopausal women suffer from osteopenia and osteoporosis in the seven major markets. Those diagnosed are often identified through screening for low bone mineral density or after presenting with a fracture. Although not all guidelines are clear on when to initiate pharmacological treatment, most base their assessment of the type of drug to treat with on cost-benefit analyses.
-- Patient segmentation by disease severity as defined by the WHO; including osteopenia, osteoporosis, and severe/established osteoporosis
-- Analysis of presentation, diagnosis, and treatment trends as well patient referral pathways in each of the major regions
-- Treatment trends split by line of therapy and disease severities, including drug switching behaviors in each of the seven major market regions
-- Prescriber scoring of key drug brands on factors including efficacy, side effects, dosing flexibility, formulations, patient compliance, and cost
Highlights of this title
The asymptomatic characteristics of osteoporosis, the fact that the majority of fractures remain undetected and the lack of nationwide screening means that osteoporosis is severely under-diagnosed.
About two-thirds of the patients are treated initially by a specialist and stay with the specialist for long-term treatment across the seven major markets, although a small group of patients switch from initial treatment by a specialist to long-term treatment under their general practitioner.
The most important factors that physicians consider when prescribing drugs for osteoporosis are efficacy on bone mineral density and fracture risk reduction. Bisphosphonates reached similar scores on efficacy and safety in The physician survey, but are differentiated in terms of cost, flexibility of administration, and intermittent dosing.
Key reasons to purchase this title
-- Target physicians more effectively through an understanding of prescribing behavior and its influences.
-- Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products.
-- Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies.
Key Topics Covered: - Country Treatment Trees - Disease Background and Epidemiology - Presentation, Diagnosis and Treatment Rates - Treatment Options and Trends - Prescribing Influences and Brand Assessment - List of Tables - List of Figures
For more information visit http://www.researchandmarkets.com/research/4a693a/stakeholder_insigh